NCT00424853已完成2 期
Randomized Phase II Trial of Two Sequential Schedules of Docetaxel and Cisplatin Followed by Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 88
- 试验地点
- 1
- 主要终点
- overall response rate assessed by RECIST criteria.
研究概览
简要总结
This is a multicenter, open-label, randomized phase II trial whose aim is to assess the antitumor activity of two sequential schedules of docetaxel and cisplatin followed by gemcitabine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of NSCLC; Histologic subtypes may include large cell, squamous cell, or adenocarcinoma or a generic cytological diagnosis of NSCLC;
- •Patients must have a locoregionally advanced unresectable non metastatic NSCLC Stage IIIB (only N3 supraclavicular or T4 for pleural effusion) or Stage IV according to the revised International Staging System;
- •Patients must have at least one measurable lesion according to RECIST criteria.
- •Previous radical surgery (more 30 days before study entry) is allowed but a pathologic proof of progression of neoplastic disease must be documented;
- •WHO Performance Status 0 or 1 ;
- •Weight loss < 5% within the last 3 months;
- •Laboratory requirements at entry
- •Blood cell counts: Absolute neutrophils > 2.0 . 10^9/L; Platelets > 100 . 10^9/L; Hemoglobin > 10 g/dl
- •Renal function: Serum creatinine < 1 upper normal limits (UNL). In case of limit value of serum creatinine, the creatinine clearance should be > 60 mL/min
- •Hepatic functions: Serum bilirubin < 1 x UNL; ASAT and ALAT < 2.5 x UNL; Alkaline phosphatase < 5 x UNL (unless accompanied by extensive bone metastases)
排除标准
- •Prior systemic chemotherapy or immunotherapy ; prior neoadjuvant or adjuvant chemotherapy is allowed if ended at least 12 months before enrollment;
- •Prior radiotherapy for NSCLC to measurable lesions. Prior radiotherapy (to < 25% of the bone marrow) is allowed in non target lesions. At least 4 weeks must be elapsed since the completion of the radiotherapy and the patient must have all side effects recovered.
- •Cyto-histological diagnosis of small cell lung cancer, carcinoid, or mixed small-cell / non-small cell lung cancer;
- •Patients with evaluable, not measurable disease only (non target lesions);
- •Patients with symptomatic brain metastases or with leptomeningeal disease;
- •History of prior malignancies, except for cured non melanoma skin cancer, curatively treated in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least five years;
- •History of hypersensitivity reaction to polysorbate 80;
- •Pregnant or lactating women (women of childbearing potential must use adequate contraception);
- •Current peripheral neuropathy NCI grade > 2;
- •Significant neurological or psychiatric disorders ;
- •Participation in clinical trials with other experimental agents within 30 days of study entry;
- •Other serious concomitant illness of medical conditions:
- •Uncontrolled cardiovascular disease;
- •History of significant neurologic or psychiatric disorders including demential or seizures;
- •Active infection requiring iv antibiotics;
- •Active ulcer, unstable diabetes mellitus or other contra-indication to corticotherapy;
- •Any other condition which in the judgement of the investigator would place the subject at undue risk or interfere with the study.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
A
Experimental
干预措施: docetaxel and cisplatin followed by gemcitabine (Drug)
B
Experimental
干预措施: docetaxel and cisplatin followed by gemcitabine (Drug)
结局指标
主要结局
overall response rate assessed by RECIST criteria.
时间窗: before, during and at the end of treatment
次要结局
- Time to progression(from the date of randomization to the date of first documented tumor progression or relapse)
- time to treatment failure(from the date of treatment start to the date of diagnosis of progression, withdrawal from study treatment for any reason, administraztion of other antitumor treatment, or death for any cause)
- overall survival(time interval from the date of randomisation to the date of death)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)Metastatic Prostate CancerNCT04332744MedSIR54
招募中
1 期
IN10018 Combination Therapy in Treatment-naïve ES-SCLCSmall Cell Lung Cancer Extensive StageNCT06030258InxMed (Shanghai) Co., Ltd.120
进行中（未招募）
2 期
Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical CancerCervical CancerNCT03340376Universitaire Ziekenhuizen KU Leuven48
尚未招募
1 期
IN10018 Combination Therapy in Previously-treated Solid TumorsSolid TumorNCT05982522InxMed (Shanghai) Co., Ltd.72
已完成
2 期
SPIRITT - Second-Line Panitumumab Irinotecan Treatment TrialMetastatic CancerRectal CancerMetastatic Colorectal CancerColon CancerColorectal CancerCancerNCT00418938Amgen266